The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Subscribe To Our Newsletter & Stay Updated
